Shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) rose 14.6% during trading on Wednesday . The company traded as high as $1.82 and last traded at $1.81. Approximately 726,910 shares were traded during trading, an increase of 462% from the average daily volume of 129,359 shares. The stock had previously closed at $1.58.

SRRA has been the subject of a number of analyst reports. Zacks Investment Research raised shares of ProNAi Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. ValuEngine raised shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Jefferies Group LLC reissued a “hold” rating on shares of ProNAi Therapeutics in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $4.00.

The company’s market cap is $94.61 million. The company’s 50 day moving average is $1.57 and its 200-day moving average is $1.57.

ProNAi Therapeutics (NASDAQ:SRRA) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Equities analysts predict that ProNAi Therapeutics, Inc. will post ($0.90) earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of SRRA. Perceptive Advisors LLC acquired a new position in shares of ProNAi Therapeutics during the first quarter valued at about $5,667,000. Sabby Management LLC acquired a new position in shares of ProNAi Therapeutics during the first quarter valued at about $2,672,000. PNC Financial Services Group Inc. acquired a new position in shares of ProNAi Therapeutics during the first quarter valued at about $1,142,000. Nexthera Capital LP acquired a new position in shares of ProNAi Therapeutics during the first quarter valued at about $612,000. Finally, FMR LLC acquired a new position in shares of ProNAi Therapeutics during the first quarter valued at about $302,000. Hedge funds and other institutional investors own 55.72% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ProNAi Therapeutics, Inc. (SRRA) Stock Price Up 14.6%” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/04/pronai-therapeutics-inc-srra-stock-price-up-14-6.html.

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Receive News & Stock Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related stocks with our FREE daily email newsletter.